TARGRETIN

Targretin Adverse Events Reported to the FDA Over Time

How are Targretin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Targretin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Targretin is flagged as the suspect drug causing the adverse event.

Most Common Targretin Adverse Events Reported to the FDA

What are the most common Targretin adverse events reported to the FDA?

Headache	20 (2.29%)
Fatigue	16 (1.83%)
Hypertriglyceridaemia	16 (1.83%)
Hypothyroidism	16 (1.83%)
Asthenia	14 (1.6%)
Dehydration	14 (1.6%)
Pneumonia	14 (1.6%)
Dyspnoea	13 (1.49%)
Pyrexia	11 (1.26%)
Anaemia	10 (1.14%)
Disease Progression	10 (1.14%)
	Show More
General Physical Health Deteriorati...	10 (1.14%)
Confusional State	9 (1.03%)
Leukopenia	9 (1.03%)
Malignant Neoplasm Progression	9 (1.03%)
Cardiac Failure	8 (.92%)
Febrile Neutropenia	8 (.92%)
Skin Exfoliation	8 (.92%)
Condition Aggravated	7 (.8%)
Erythema	7 (.8%)
Insomnia	7 (.8%)
Myalgia	7 (.8%)
Nausea	7 (.8%)
Neoplasm Malignant	7 (.8%)
Oedema Peripheral	7 (.8%)
Visual Impairment	7 (.8%)
Chills	6 (.69%)
Choroiditis	6 (.69%)
Depressed Mood	6 (.69%)
Drug Interaction	6 (.69%)
Dysuria	6 (.69%)
Hyperhidrosis	6 (.69%)
Hypoxia	6 (.69%)
International Normalised Ratio	6 (.69%)
Mycosis Fungoides	6 (.69%)
Pain	6 (.69%)
Pruritus	6 (.69%)
Blood Triglycerides Increased	5 (.57%)
Cardiac Failure Congestive	5 (.57%)
Cough	5 (.57%)
Haematochezia	5 (.57%)
International Normalised Ratio Incr...	5 (.57%)
Oxygen Saturation Decreased	5 (.57%)
Sepsis	5 (.57%)
Subdural Haematoma	5 (.57%)
Thrombocytopenia	5 (.57%)
Abdominal Pain	4 (.46%)
Arthralgia	4 (.46%)
Cerebrovascular Accident	4 (.46%)
Deafness	4 (.46%)
Death	4 (.46%)
Dizziness	4 (.46%)
Drug Ineffective	4 (.46%)
Face Oedema	4 (.46%)
Granuloma	4 (.46%)
Haematuria	4 (.46%)
Haemoglobin Decreased	4 (.46%)
Haemoptysis	4 (.46%)
Lymphoma	4 (.46%)
Pulmonary Fibrosis	4 (.46%)
Rash	4 (.46%)
Renal Failure Acute	4 (.46%)
Vomiting	4 (.46%)
White Blood Cell Count Increased	4 (.46%)
Abasia	3 (.34%)
Acute Coronary Syndrome	3 (.34%)
Blood Cholesterol Abnormal	3 (.34%)
Blood Creatinine Increased	3 (.34%)
Blood Triglycerides Abnormal	3 (.34%)
Cardiac Arrest	3 (.34%)
Coagulopathy	3 (.34%)
Delirium	3 (.34%)
Dermatitis Exfoliative	3 (.34%)
Diverticulitis	3 (.34%)
Dry Skin	3 (.34%)
Ecchymosis	3 (.34%)
Flank Pain	3 (.34%)
Hyperlipidaemia	3 (.34%)
Hypoglycaemia	3 (.34%)
Hypotension	3 (.34%)
Infection	3 (.34%)
Lung Infection	3 (.34%)
Lymphadenopathy	3 (.34%)
Myoglobin Blood Increased	3 (.34%)
Nephrolithiasis	3 (.34%)
Night Sweats	3 (.34%)
Pancreatic Carcinoma	3 (.34%)
Pericardial Effusion	3 (.34%)
Pleural Effusion	3 (.34%)
Pulmonary Hypertension	3 (.34%)
Pulmonary Mass	3 (.34%)
Retinoic Acid Syndrome	3 (.34%)
Skin Necrosis	3 (.34%)
Sudden Hearing Loss	3 (.34%)
Abnormal Dreams	2 (.23%)
Acne	2 (.23%)
Anaemia Haemolytic Autoimmune	2 (.23%)
Anxiety	2 (.23%)
Aortic Dilatation	2 (.23%)
Apathy	2 (.23%)
Atrial Flutter	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Targretin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Targretin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Targretin

What are the most common Targretin adverse events reported to the FDA?

Epidermal And Dermal Conditions	51 (5.84%)
Respiratory	43 (4.92%)
Hematology Investigations	37 (4.23%)
Infections - Pathogen Unspecified	34 (3.89%)
White Blood Cell	26 (2.97%)
Gastrointestinal Signs	21 (2.4%)
Lipid Metabolism	21 (2.4%)
Headaches	20 (2.29%)
Miscellaneous And Site Unspecified ...	19 (2.17%)
Electrolyte And Fluid Balance Condi...	17 (1.95%)
Thyroid Gland	17 (1.95%)
	Show More
Urinary Tract Signs	15 (1.72%)
Deliria	14 (1.6%)
Heart Failures	13 (1.49%)
Anemias Nonhemolytic And Marrow Dep...	12 (1.37%)
Lipid Analyses	12 (1.37%)
Lower Respiratory Tract Disorders	12 (1.37%)
Therapeutic And Nontherapeutic Effe...	12 (1.37%)
Body Temperature Conditions	11 (1.26%)
Hearing	11 (1.26%)
Muscle	11 (1.26%)
Skin Appendage Conditions	11 (1.26%)
Bacterial Infectious	10 (1.14%)
Central Nervous System Vascular	10 (1.14%)
Neurological	10 (1.14%)
Cardiac Arrhythmias	9 (1.03%)
Depressed Mood Disorders	9 (1.03%)
Gastrointestinal Hemorrhages	9 (1.03%)
Sleep Disorders	9 (1.03%)
Vision	9 (1.03%)
Embolism And Thrombosis	8 (.92%)
Lymphomas Non-hodgkins T-cell	8 (.92%)
Musculoskeletal And Connective Tiss...	8 (.92%)
Injuries	7 (.8%)
Ocular Infections, Irritations And ...	7 (.8%)
Decreased And Nonspecific Blood Pre...	6 (.69%)
Hepatobiliary	6 (.69%)
Metastases	6 (.69%)
Renal And Urinary Tract Investigati...	6 (.69%)
Renal Disorders	6 (.69%)
Appetite And General Nutritional	5 (.57%)
Coronary Artery	5 (.57%)
Joint	5 (.57%)
Metabolic, Nutritional And Blood Ga...	5 (.57%)
Platelet	5 (.57%)
Anxiety Disorders	4 (.46%)
Bone Disorders	4 (.46%)
Chemical Injury And Poisoning	4 (.46%)
Disturbances In Thinking	4 (.46%)
Fatal Outcomes	4 (.46%)
Fungal Infectious	4 (.46%)
Inner Ear And Viiith Cranial Nerve	4 (.46%)
Lymphomas	4 (.46%)
Personality Disorders	4 (.46%)
Pleural	4 (.46%)
Pulmonary Vascular	4 (.46%)
Tissue	4 (.46%)
Coagulopathies And Bleeding Diathes...	3 (.34%)
Endocrine Neoplasms Malignant And U...	3 (.34%)
Gastrointestinal Neoplasms Malignan...	3 (.34%)
Glucose Metabolism Disorders	3 (.34%)
Hemolyses And Related Conditions	3 (.34%)
Musculoskeletal And Soft Tissue Inv...	3 (.34%)
Pericardial	3 (.34%)
Skin Vascular Abnormalities	3 (.34%)
Spleen, Lymphatic And Reticulendoth...	3 (.34%)
Urolithiases	3 (.34%)
Arteriosclerosis, Stenosis, Vascula...	2 (.23%)
Bone, Calcium, Magnesium And Phosph...	2 (.23%)
Cardiac And Vascular Investigations	2 (.23%)
Cardiac Disorder Signs	2 (.23%)
Dental And Gingival Conditions	2 (.23%)
Endocrine Investigations	2 (.23%)
Enzyme	2 (.23%)
Gastrointestinal Motility And Defec...	2 (.23%)
Gastrointestinal Ulceration And Per...	2 (.23%)
Hematological And Lymphoid Tissue T...	2 (.23%)
Hematopoietic Neoplasms	2 (.23%)
Hepatic And Hepatobiliary	2 (.23%)
Lifestyle Issues	2 (.23%)
Lymphomas Non-hodgkins B-cell	2 (.23%)
Mood Disorders	2 (.23%)
Neoplasm Related Morbidities	2 (.23%)
Nervous System Neoplasms Benign	2 (.23%)
Ocular Hemorrhages And Vascular	2 (.23%)
Oral Soft Tissue Conditions	2 (.23%)
Peripheral Neuropathies	2 (.23%)
Physical Examination Topics	2 (.23%)
Respiratory And Mediastinal Neoplas...	2 (.23%)
Sexual Dysfunctions, Disturbances A...	2 (.23%)
Sexual Function And Fertility	2 (.23%)
Structural Brain	2 (.23%)
Suicidal And Self-injurious Behavio...	2 (.23%)
Vascular	2 (.23%)
Vitamin Related	2 (.23%)
Administration Site Reactions	1 (.11%)
Allergic Conditions	1 (.11%)
Anterior Eye Structural Change, Dep...	1 (.11%)
Benign Neoplasms Gastrointestinal	1 (.11%)
Gallbladder	1 (.11%)
Gastrointestinal	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Targretin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Targretin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.